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The Women’s Health Initiative Studies (WHI) were designed to examine the effects of estrogen and progestin
(E+P; Prempro) and estrogen alone (Premarin) in post-menopausal women.The authors of the WHI studies
and the National Heart Lung and Blood Institute (NHLBI) concluded that E+P treatment increased the risks of
coronary heart disease, invasive breast cancer, stroke and venous thromboembolism.The following paper
contains a reevaluation of these studies based on the graphic analysis of their tabulated data. In contrast to
the conclusions reached by the WHI and the NHLBI, I conclude that treatment of post-menopausal women
with estrogen and progestin (Prempro) does not increase the risks of cardiovascular disease, invasive breast
cancer, stroke or venous thromboembolism. I also disagree with the claim that an increased risk of stroke
existed in women treated with estrogen alone.
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Introduction
The purpose of this paper is to point out problems with
the data analysis and conclusions drawn by the authors
of the Women’s Health Initiative (WHI) studies published
over the time period 2002-2006.The WHI was a
randomized placebo controlled clinical trial to examine
the effects of estrogen plus progestin on various health
benefits and risks in post-menopausal women [Rossouw
et al., 2002].The trial was designed to last for 8.5 years
but was stopped at 5.2 years because the National Heart,
Lung and Blood Institute (NHLBI) accepted the study’s
Data and Safety Monitoring Board (DSMB) evaluation
that the risks of breast cancer were increased and other
health risks of hormone treatment were greater than the
benefits [NHLBI, 2002]. Additional papers which extended
the evaluation of these data were published on two
subgroups of stroke [Wassertheil-Smoller et al., 2003],
coronary heart disease [Manson et al., 2003] and breast
cancer [Chlebowski et al., 2003].
The conclusions drawn from the first paper have been
widely accepted as demonstrating that combined estrogen
plus progestin (E+P: Prempro: 0.625 mg conjugated
estrogens and 2.5 mg medroxyprogesterone acetate)
replacement treatment in postmenopausal women
increased the risk of invasive breast cancer (IBC),
coronary heart disease (CHD), stroke and venous
thromboembolism (VTE) [Fletcher and Colditz, 2002;
Gann and Morrow, 2003; National Cancer Institute, 2002;
NHLBI, 2002; Pedersen and Ottesen, 2003].The
conclusions in these papers were derived from Kaplan
Meier estimates of cumulative hazards and Cox
proportional hazard models [Cox, 1972].These are the
accepted methods for analyzing such data; however, I
feel the conclusions drawn were incorrect and statistical
methods used require modification.
The WHI also included a parallel study which examined
the risk versus benefits of estrogen treatment alone
(Premarin) in post-menopausal women.This arm of the
WHI was continued until February 2004, which was
approximately eight months earlier than the intended
termination date of October 2004 to March 2005
[Anderson et al., 2004].
The authors concluded that use of conjugated equine
estrogens increased the risk of stroke, decreased the risk
of hip fracture and did not affect CHD and may reduce
the risk of breast cancer. In the final paper on CHD it was
concluded that there might be a protective effect in 50-59
year old women [Hsia et al., 2006]; that there was no
increase in breast cancer [Stefanick et al., 2006] and that
an early increase in venous thrombosis is associated with
the use of estrogen alone [Curb et al., 2006]. As in the
E+P studies cited previously, I believe these conclusions
to be either incorrect or require important modifications.
Relative risks versus absolute risks
One of the major problems with the interpretation and
misunderstandings of this study was that it emphasized
the use of relative risks rather than absolute risks.The
latter provides a much more reasonable and
understandable appraisal of the data. For example, the
authors state that there was a 29% increase in CHD in
the E+P group compared to the placebo group.This 29%
value is a relative risk and is derived from the Hazard
Ratio (1.29), which is calculated from the Cox Regression
analysis used by these authors. Relative risk can be
misleading and many people do not realize that the actual
increases are very small and may be insignificant.The
actual % increase is 0.07% which can be calculated from
the following information:
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in a population of 10,000.Thus the number of individuals
affected was 37. Since the incidence in the placebo group
was 0.30% of 10,000, the number affected was 30. So
the actual increase in patients with CHD was 7/10,000
or a 0.07% increase in absolute risk. Note that these
increases were judged in the final analyses to be
statistically insignificant.This is especially important when
these results are presented by the media to the general
public.The relationships between hazard ratios, relative
risks and absolute risks are shown in Table 1. Some
scientists considered such small absolute risks as
statistically insignificant, and when all the results were
published this supposition was correct.
This difference between relative and absolute risks has
been pointed out by others, but has received little
attention or emphasis [Goodman et al., 2003; Kelly, 2002;
McDonough, 2002].The Consolidated Standards of
Reporting Trials (CONSORT) indicated that authors
should state results as absolute, not just relative numbers
[Moher et al., 2001]. In addition, many authors agree that
unless a hazard ratio is 3.0 or higher it is of no
consequence [Taubes, 1995].Therefore, by this standard,
all of the hazard ratios in this study would be considered
insignificant.
Coronary heart disease (CHD) in the
2002 paper
Risk ratio
As discussed previously, the authors report a hazard ratio
of 1.29 or a 29% relative risk for CHD in the E+P treated
group.They state that this value reached nominal
statistical significance; however, this statement is based
on nominal (unadjusted) confidence intervals which
should not be used in this type of study as indicated by
them in their paper on page 325. If adjusted confidence
intervals had been used, the HR of 1.29 would not have
reached statistical significance.
Most of the WHI papers display data in tables as
incidence of disease per year of hormone or placebo
treatment. I have taken the incidence data for the two
groups and calculated risk ratios (% incidence in hormone
group/% incidence in the placebo group) and plotted these
as a function of time in years (Figure 1). It is apparent
that 4 of the total 6 values for CHD are equal to or very
near to the no effect value of 1.0 (Figure 1A).The peak
in risk ratio at year 5 is not due to a significant increased
incidence of CHD in the E+P group, but to a decreased
incidence in the placebo group (Figure 1B).
The final hazard ratio of 1.29 has an adjusted 95%
confidence interval of 0.85-1.97. Such a broad confidence
interval, which includes 1.0, and the fact that four of six
risk ratio values are not different from the no effect level,
demonstrate that there is no significant increase in
absolute risk. As discussed below, the authors conclude
in a later paper that the risks for CHD are not significant
(Figure 2A and Figure 2B below; [Manson et al., 2003]).
Incidence
The risk ratios in Figure 1A are derived from the erratic
incidence values for CHD which increase and decrease
between 0.2 and 0.4% as a function of time (Figure 1B).
The values for both groups vary over a similar range and
the differences are very small. Since the WHI study was
done with older women, averaging 12 years
post-menopausal, the elevated value for the risk ratio at
year 1 may be due to the presence of asymptomatic
atherosclerosis as a result of the loss and absence of
endogenous estrogen following the onset of menopause
[Grodstein et al., 2006; Harman et al., 2005;Turgeon et
al., 2004]. Judging from variable incidence values in
Figure 1B for the placebo group, the elevated risk at year
1 could be due to chance. Certainly the sudden peak in
the risk ratio at year 5 is not due to a sudden increase in
CHD, but instead, to an accompanying drop in values for
the placebo group (Figure 1B). It seems obvious that no
significant differences exist between incidence of CHD
in the E+P and placebo groups when these data are
viewed in a graphic format; however, such differences
are not so obvious when the data are in table form.
Coronary heart disease (CHD) in the
2003 paper
In a final report on CHD the WHI authors provide an
analysis which does not support the original statement
of a significant increased risk of CHD in women treated
with E+P [Manson et al., 2003]. Instead, they conclude
that E+P treatment may increase risks of CHD during the
first year, but after that the risk decreases with time and
this downward trend is statistically significant.The CHD
hazard ratios for each year from that paper are shown in
Figure 2A.The unadjusted 95% CI for these HR values
are very wide and all but the first year value include the
no effect level of 1.0. If adjusted 95% CIs had been used,
all would have included 1.0.The peak at year 5 has
decreased because the incidence of CHD in the placebo
group has increased (compare Figure 2B with Figure 1B).
As stated above, the incidence of CHD in the placebo
group, not an increase in incidence of CHD in the E+P,
accounted for the 5 year peak in risk in the 2002 paper.
The final hazard ratio was 1.24 or an absolute increase
of 0.06%, which is equal to 6 additional CHD events per
10,000 person years.They conclude that no significant
increased risk of CHD is associated with E+P treatment.
I believe this conclusion could have been reached in 2002
when the study was prematurely halted.
Coronary heart disease in the estrogen
only study
In this study the authors conclude that estrogen alone
does not affect the risk of CHD in post-menopausal
women (HR, 0.91; 95% CI, 0.75-1.12; [Anderson et al.,
2004]).The final results of the estrogen alone study were
divided into age groups of 50-59, 60-69 and 70-79 years
[Hsia et al., 2006].The conclusion was that estrogens
provide no protection against CHD with the possible
exception of those in the 50-59 age group (HR, 0.61; 95%
nominal CI, 0.25-1.50). However, the incidence and risk
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Perspective WHI critiqueTable 1. Relationship between hazard ratios, relative risks and absolute risks in the WHI study. These data were taken from Writing group
for the WHI, 2002. * None of the numbers were judged to be statically significant when all data analysis had been completed; therefore, they do not
constitute actual increases in risks.The only possible exception is the risk of hip fracture, which was judged by the WHI authors to be significantly
reduced. ** The number of outcomes is expressed per 10,000 for ease in numerical comparison.The actual number of individuals per group was 8,506
and 8,102 in the E+P and placebo groups, respectively.
Figure 1. Coronary heart disease (CHD) in 2002 paper. A. Risk ratios calculated from incidence data. B. Incidence of CHD. All data were taken
from Table 4 in the WHI 2002 publication.
ratio data for CHD in each of these groups is more erratic
and variable than any of the data shown thus far.These
results will be the subject of another paper and will not
be discussed further here.
Invasive breast cancer (IBC) 2002 paper
Risk ratio
The value of 26% increase in the relative risk of invasive
breast cancer in the E+P group has been cited over and
over by many people in the scientific and non-scientific
media, even though the authors of the WHI paper
acknowledge that it “almost reached nominal statistical
significance”. Since “almost” is not statistical significance,
the statement should have been: there was no significant
difference in IBC risk between the placebo group and the
E+P group. As in the analysis of CHD, if the authors had
used adjusted confidence intervals there would be no
doubt that risks were not increased.
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(CHD). All data were taken from Table 2 in the WHI 2003 publication.
The authors then indicate that “the weighted test statistic
used for monitoring was highly significant”.This statistic
would not have been elevated if the authors had
examined the data more carefully.The apparent increase
in risk ratios from years 2-5 is accompanied by a decline
in the placebo groups (Figure 3A and Figure 3B). As
discussed below, in the final analysis of these data this
upward trend is not statistically significant (Figure 4A and
Figure 4B).The final hazard ratio of 1.26 has an adjusted
95% confidence interval of 0.83-1.92, and the absolute
risk increase is 0.08% or 8/10,000 person years. Such a
broad confidence interval which includes 1.0 indicates
there is no significant increase in risks due to hormone
use. In addition, mere inspection of the data in Figure 3A
clearly shows that four of the six values are not different
from the no effect level, thus making it very unlikely that
any real differences in risk existed.
Incidence (detection)
The percent incidence or detection, a more valid term, of
breast cancer was similar up to year 3 with the detection
level for the E+P group below that of the placebo group
in years 1-2 (Figure 3B). By years 4 and 5 the two groups
appear to diverge with the E+P group being greater than
the placebo group. However, by year 6 the two groups
came back together and were not different from one
another.This divergence and convergence of detection
at these times accounts for the spike in the risk ratios
seen in Figure 3A. As discussed above, it is difficult to
see how such data could be considered to be predictive
of risk since 4 of the 6 risk ratio values are not different
from the no effect level of 1.0 and during the last year the
detection level in the placebo group increased
dramatically.
The term detection is used instead of incidence because
incidence implies cause and it is very unlikely that any
breast cancer detected in this study was initiated by the
hormone therapy. Other investigators have pointed out
that the time between initiation of breast cancer and the
time that cancer can be detected varies between 10 to
20 years [Dietel et al., 2005; Koscielny et al., 1985; von
Fournier et al., 1980].
Invasive breast cancer (IBC) 2003 paper
In a subsequent more detailed paper on the effects of
E+P treatment on IBC the authors provide hazard ratios
and their respective non-adjusted 95% CI intervals in
table form (Figure 4A; [Chlebowski et al., 2003]).When
these data are compared to those in Figure 3A we can
see the hazard ratios for years 4 and 5 have been
reduced from 1.73 to 1.54 (CI, 0.95-2.49) for year 4, and
2.64 to 1.99 (CI, 1.18-3.35) for year 5.The value for year
5 appears to be significant; however, the 95% CI is not
adjusted, therefore it is not possible to judge with
certainty. If an adjusted 95% CI had been used it probably
would have included 1.0.
These lower HR values and broad non-adjusted 95%
confidence intervals provide even more reasons to doubt
the conclusions drawn by the WHI authors and the NHLBI
that a significant increase in risks for IBC occurred in this
study. Such doubt is amplified by the data on hazard
ratios for IBC in women who had used or had not used
post-menopausal hormones before the study (Figure 5A
and Figure 5B).The hazard ratios for women with prior
use are very variable and the unadjusted 95% confidence
intervals are extremely large.Therefore, it seems unlikely
that any meaningful conclusion can be drawn from this
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WHI 2002 publication.
Figure 4. Invasive breast cancer (IBC) 2003. A. Hazard ratios. B. Detection of invasive breast cancer (IBC) in the all women regardless of prior
hormone use. All data were taken from Table 2 in the WHI 2003 publication.
group. In the group without prior use of hormones the
hazard ratios look almost identical to those in Figure 2A,
however the 95% CIs are larger. Four of the six HR values
are below or near the no effect level and all 95% CIs
overlap it. If adjusted CIs had been used, all would have
included 1.0.Therefore, it seems impossible to draw any
meaningful conclusions from such data.
Invasive breast cancer in the estrogen
only studies
In the estrogen only arm of the WHI study invasive breast
cancer was decreased by estrogen treatment [Anderson
et al., 2004].The hazard ratio was not statistically
significant: 0.77 (CI, 0.59-1.01). A protective effect may
be likely since the number of risk ratios which were near
or below the no effect level were greater than those above
this level (data not shown). In the final report on this
aspect of the study similar data and conclusions were
reached [Stefanick et al., 2006].
Venous thromboembolism (VTE) 2002
paper
Risk ratio
Similar criticisms to those above can be made of the VTE
data.The authors indicate that there was a 2 fold
increased risk of VTE in the E+P group (Figure 6A).This
2 fold increase constitutes an absolute risk of 0.18% for
VTE in the E+P group compared to the placebo group.
The final hazard ratio was reported as 2.22 with an
adjusted 95% confidence interval of 1.26-3.55.The
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in women with prior use of hormones. B. Detection of IBC in women with no prior use of hormones. All data were taken from Table 2 in the WHI 2003
publication.
authors do not indicate whether they believe this value
is significant. However, as indicated previously, such
broad confidence intervals in association with an overall
decrease in risk ratios over time make it unlikely that
these data demonstrate any actual risk.
Incidence
The downward trend in risk ratios discussed previously
is the result of a relatively higher incidence of VTE during
the first year in the E+P group (Figure 6B).These higher
values decline with time and are not different from the
placebo group in year 6.These data show an overall
downward occurrence of VTE in the E+P group. Certainly
not an increased risk as claimed in the WHI paper in the
NHLBI news release. As discussed above, these early
occurrences may be due to the presence of asymptomatic
atherosclerosis or clotting defects in these older women.
Venous thromboembolism in the
estrogen only study
No data on a yearly basis were published for VTE in the
estrogen only study; therefore, it was not possible to
graph risk ratios or percent incidence as a function of
time [Anderson et al., 2004].The authors indicate the
final hazard ratio was 1.33 (95% CI, 0.86-2.08) and that
this was not significant. However, they say that the risk
for the subgroup, deep vein thrombosis (DVT), is
significant (HR 1.47; CI, 0.87-2.47). Since no yearly data
were provided for DVT it was not possible to draw a
graph; however, the authors did provide yearly data for
pulmonary thrombosis (PE) which show the same erratic
risk ratio and incidence values as in most of their other
data (data not shown).Therefore, it is likely that the data
for deep vein thrombosis shows similar, if not greater
variation.This likelihood, plus the small absolute increase
(0.06%) and the broad confidence intervals which cross
1.0, make it difficult to accept these values as significant.
This expectation of a high degree of variability and
uncertainty was borne out by the data in the final paper
from the WHI studies on venous thrombosis [Curb et al.,
2006]. In this paper the authors provide hazard ratios and
non-adjusted 95% confidence intervals for DVT, PE and
venous thrombosis, VT (Figure 7). If adjusted 95% CIs
had been used, all values would have included 1.0 and
would have been judged insignificant. It is clear why the
authors of this paper make no statement concerning
statistical significance. Instead, they state that VT risk is
associated with the use of estrogen during the first two
years of exposure. It is clear that the very wide
non-adjusted confidence intervals associated with the
0-2 year span for all three groups make it impossible to
conclude anything concerning this period.The later time
periods show no increased risk due to hormone treatment.
It is puzzling why the authors in the 2004 paper conclude
that the HR for DVT is significant and yet in the 2006




The risk ratios for stroke in the E+P group increased from
no effect at the first year to 1.72 by the second year and
remain at about this level for the next four years (95%
confidence intervals for each year were not published).
Then by year 6 the risk ratio is below the no effect level
(0.66; Figure 8A).The final hazard ratio determined by
the WHI authors of 1.41 has an adjusted 95% confidence
interval of 0.86-2.31. Such broad confidence intervals
which include 1.0 are not significant. Once again the
absolute risk is extremely low (0.08%), making it unlikely
that these data demonstrate any clinically significant risk.
The authors of the 2002 paper make no judgment as to
the statistical significance of these data; however, the
www.nursa.org  NRS  | 2006 |  Vol. 4 |  DOI: 10.1621/nrs.04023 | Page 6 of 10
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4 in the WHI 2002 publication.
Figure 7. Hazard ratios for deep vein thrombosis [A], pulmonary embolism [B] and venous thrombosis [C].  Error bars show the 95% CIs
for the hazard ratios. Data taken from Table 6 in Curb et al 2006.Time periods: 1 = 0-2 yrs, 2 = 2-5 yrs, 3 = 5 or greater yrs.
NHLBI assumed the increase of 41% was significant and
indicated this in their news release.
In a subsequent paper, the effects of E+P on ischemic
and hemorrhagic stroke were examined
[Wassertheil-Smoller et al., 2003]. Since no data for risk
ratios or incidence for each year of the study were
provided, no graphs similar to those in Figure 8 above
could be drawn.The final hazard ratio for total strokes
was 1.31 (95% CI, 1.02-1.68), which the authors claim is
significant. However, the adjusted 95% CI was 0.93-1.84,
which makes this value statistically insignificant.The
hazard ratios for hemorrhagic and ischemic stroke were
judged to be statistically insignificant.
Stroke in the estrogen only study
Risk ratios and incidence
The risk ratios for stroke in this study are low but generally
above the no effect level (Figure 9A).These minimal ratio
values are the result of very variable incidence levels,
which indicate that these groups were not different from
one another for the first five years of the study (Figure
9B).This period is followed by a small increase in the
estrogen group at year 5, which is followed by a steady
decline to low levels equal to those of the placebo group.
Such declines in the risk ratio and incidence in the
estrogen group suggest a beneficial effect of estrogen
treatment.The authors indicate that the final hazard ratio
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Perspective WHI critiqueFigure 8. Stroke. A. Risk ratios. B. Incidence of stroke. All data were taken from Table 4 in the WHI 2002 publication.
of 1.39 was significant; however, this was based on
non-adjusted 95% CI.When the adjusted 95% CI is used
(0.97-1.99), the HR becomes statistically insignificant.
Colorectal and endometrial cancer
In the E+P and E-alone studies the number of women is
small and the incidence levels are in the 0.1% range (data
not shown).The final hazard ratio for the E+P studies
was 0.63 (95% CI, 0.32-1.24) and was considered by the
authors to be significant. In contrast, the risk for colorectal
cancer in the estrogen only group was judged to be
insignificant.The authors conclude that the incidence of
endometrial cancer in the E+P group was not affected
since the final hazard ratio was 0.83 (95% CI, 0.29-2.32).
Hip fracture
The incidence of hip fracture in the E+P and E-alone
studies are low and the risk ratios are all below 1.0, and
the authors indicate these are significant reductions.
Global index
The authors state that the global index in the E+P study
was significantly increased; however, the HR of 1.15 and
an adjusted 95% CI of 0.95-1.39, indicates that it is not
significant.This 15% increase is actually an increase of
19/10,000 or 0.19% in absolute risk.When the global
index ratio is viewed on an annual basis four values are
very near or below the no effect level of 1.0 and the other
two are low (not shown), and it is difficult to see how such
data could have any significance. In the E-only study the
global index was 1.01 (CI: 0.89-1.14) and was judged by
the authors to be insignificant.
Conclusions
The WHI study of E+P has received much acclaim and
praise [Fletcher and Colditz, 2002; National Cancer
Institute, 2002]. Although the methods are generally
accepted as being appropriate for such clinical studies,
I believe the conclusions drawn were incorrect as a result
of the use of unadjusted 95% CIs and failure to closely
examine incidence data. It is difficult to believe that any
elevated risks exist when graphs of risk ratios and disease
incidence show no differences from control or from the
no effect levels.
The 5 year peak in CHD, IBC and VTE may be due to
factors other than increased risk from E+P. Possible
confounders at the 5 year time point include: (A) decrease
in event in the placebo group; and (B) a drop out rate that
was six times greater than in the preceding year [Machens
and Schmidt-Gollwitzer, 2003]. If such statistical artifacts
and circumstances had been taken into account the
overall evaluation of the WHI study would have turned
out differently and the NHLBI would not have stopped the
study prematurely. It has also been pointed out that the
decision to terminate the E+P arm of the WHI study was
based on unadjusted risk hazards for breast cancer and
cardiovascular disease [Machens and Schmidt-Gollwitzer,
2003].When confidence intervals are adjusted for multiple
testing of the hazard ratios for these two diseases they
are not statistically elevated.
In addition to my objections to the conclusions drawn by
the estrogen plus progestin study, Dietel et al. [Dietel et
al., 2005] have summarized the views of several
investigators who have indicated that the E+P WHI study
does not even qualify as a randomized placebo-controlled
study [Braendle and Kuhl, 2003; Goodman et al., 2003;
Machens and Schmidt-Gollwitzer, 2003; McDonough,
2002; Shapiro, 2003].The reasons for this statement are:
1. After randomization the women were free to decide
whether to continue their assigned treatment or whether
to undergo diagnostic procedures. 2.The rate of
unblinding in the E+P group was 45%, which means that
almost half of the women were aware of their treatment.
3. Several warnings were sent to the participants about
the detection of increased risks of myocardial infarction,
stroke and pulmonary embolism during the study.These
problems make the WHI study no better than any
observational study with all of their limitations.
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Perspective WHI critiqueFigure 9. Stroke in estrogen alone study. A. Risk Ratios. All data for risk ratios were calculated from the data in Figure 3 of the WHI 2004
publication. B. Incidence of stroke in estrogen or placebo treated groups.
In addition to all of these problems, the women in these
WHI studies were 12-15 years past the onset of
menopause.Thus, these women were without their
pre-menopausal levels of estrogen and progesterone
long enough to bring about changes in various bodily
functions which are the precursors of disease or of
undiagnosed disease. For instance, ovarian hormones
are important for maintaining normal structure and
function of the blood vascular system [Karas and
Clarkson, 2003]. Once vascular disease has begun,
hormone treatment is not likely to reverse the effects
[Naftolin et al., 2004]. Proper bone strength is maintained
by estrogen and when estrogen is no longer secreted at
menopause bones begin to lose calcium and the first
stages of osteoporosis begin. Most reproductive scientists
believe that post-menopausal hormones should be used
as preventive, not corrective therapy; therefore, treatment
should begin during the menopausal transition.
In summary, the findings of the E+P study should have
been: no significant risks were found for cardiovascular
disease, invasive breast cancer, stroke and venous
thromboembolism. Instead, the WHI authors and the
NHLBI concluded that post-menopausal hormone
treatment increased the risks for all of these diseases.
When this was released to the news media it resulted in
considerable confusion among patients and doctors alike,
and caused an untold number of women to go without
potentially beneficial hormone therapy.The final
consequences of these incorrect conclusions are yet to
be determined, but it is likely that an untold number of
women will suffer from diseases which post-menopausal
hormone treatment could have prevented.
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